Litigation Details for IBSA Institut Biochimique, S.A. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)
✉ Email this page to a colleague
IBSA Institut Biochimique, S.A. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)
| Docket | ⤷ Sign Up | Date Filed | 2018-04-13 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Patents | 7,723,390 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in IBSA Institut Biochimique, S.A. v. Teva Pharmaceuticals USA, Inc.
The small molecule drug covered by the patent cited in this case is ⤷ Sign Up .
Details for IBSA Institut Biochimique, S.A. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2019-08-20 | 107 | Opinion - Memorandum Opinion | construction of multiple terms in U.S. Patent No. 7,723 ,390 ('" 390 Patent"). (D.I. 70). I have considered… construction for multiple terms in U.S. Patent No. 7,723,390. Within five days the parties shall submit…quot; It is a bedrock principle of patent law that the claims of a patent define the invention to which …construing patent claims, a court considers the literal language of the claim, the patent specification…compositions for thyroid hormones. ('390 Patent at 1:6-7). The patent descends from an Italian priority application | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
